The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages S14-S19

  Pernambuco, Andrei Pereira ^a,b,c   Schetino, Luana Pereira Leite ^a   Viana, Renato de Souza ^d   Carvalho, Luciana de Souza Cota ^a,d   d'Ávila Reis, Débora ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Department of Health Sciences   (Brazil)

^c UNIVERSIDADE DE ITAÚNA   (Brazil)

^d São Luiz Hospital ^*  (Brazil)

Author keywords

6 sulphatoxymelatonin; Fibromyalgia; Melatonin; Pathophysiology

Indexed keywords

MELATONIN; 6-SULFATOXYMELATONIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HEALTH STATUS; HORMONE URINE LEVEL; HUMAN; MAJOR CLINICAL STUDY; PAIN ASSESSMENT; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; SATISFACTION WITH LIFE SCALE; SHORT FORM 36; ANALOGS AND DERIVATIVES; BRAZIL; CASE CONTROL STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PREDICTIVE VALUE; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SLEEP; SYNDROME; URINALYSIS; URINE;

ADULT; BIOLOGICAL MARKERS; BRAZIL; CASE-CONTROL STUDIES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROMYALGIA; HEALTH STATUS; HUMANS; MELATONIN; MIDDLE AGED; PATIENT SATISFACTION; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SLEEP; STATISTICS, NONPARAMETRIC; SYNDROME; URINALYSIS;

EID: 84928930135     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. WOLFE F, CLAUW DJ, FITZCHARLES MA et al.: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010; 62: 600-10.
2. SARZI-PUTTINI P, ATZENI F, DI FRANCO M et al.: Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. Clin Exp Rheumatol 2012; 30 (Suppl. 74): 143-51.
3. BAZZICHI L, SERNISSI F, CONSENSI A, GIACOMELLI C, SARZI-PUTTINI P: Fibromyalgia: a critical digest of the recent literature. Clin Exp Rheumatol 2011; 29 (Suppl. 69): S1-11.
4. SAUER K, KEMPER C, GLAESKE G: Fibromyalgia syndrome: prevalence, pharmacological and non-pharmacological interventions in outpatient health care. An analysis of statutory health insurance data. Joint Bone Spine 2011; 78: 80-4.
5. GUIGNARD S: Fibromyalgia: a daring new look. Clin Exp Rheumatol 2013; 31 (Suppl. 79): S3-5.
6. SPAETH M: Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009; 11: 117.
7. WIERWILLE L: Fibromyalgia: diagnosing and managing a complex syndrome. J Am Acad Nurse Pract 2012; 24: 184-92.
8. DI FRANCO M, IANNUCCELLI C, VALESINI G: Neuroendocrine immunology of fibromyalgia. Ann N Y Acad Sci 2010; 1193: 84-90.
9. RIVA R, MORK PJ, WESTGAARD RH, LUNDBERG U: Comparison of the cortisol awakening response in women with shoulder and neck pain and women with fibromyalgia. Psychoneuroendocrinology 2012; 37: 299-306.
10. CARVALHO LS, CORREA H, SILVA GC et al.: May genetic factors in fibromyalgia help to identify patients with differentially altered frequencies of immune cells? Clin Exp Rheumatol 2008; 154: 346-52.
11. PERNAMBUCO AP, SCHETINO LP, ALVIM CC et al.: Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol 2013; 31 (Suppl. 79): S60-3.
12. MAHDI AA, FATIMA G, DAS SK, VERMA NS: Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys 2011; 48: 82-7.
13. SENEL K, BAYGUTALP F, BAYKAL T, ERDAL A, UGUR M: Melatonin levels in premenopausal women with fibromyalgia syndrome. Rheumatology Int 2013: 33: 1609-10.
14. MASRUHA MR, LIN J, de SOUZA VIEIRA DS et al.: Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache 2010; 50: 413-9.
15. KLERMAN EB, GOLDENBERG DL, BROWN EN, MALISZEWSKI AM, ADLER GK: Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 2001; 86: 1034-9.
16. KORSZUN A, SACKETT-LUNDEEN L, PAPADOPOULOS E et al.: Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999; 26: 2675-80.
17. WIKNER J, HIRSCH U, WETTERBERG L, ROJDMARK S: Fibromyalgia--a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxford) 1998; 49: 179-83.
18. PRESS J, PHILLIP M, NEUMANN L et al.: Normal melatonin levels in patients with fibromyalgia syndrome. J Reumatol 1998; 25: 551-5.
19. VANECEK J: Cellular mechanisms of melatonin action. Physiological reviews 1998; 78: 687-721.
20. BAILEY MJ, COON SL, CARTER DA et al.: Night/day changes in pineal expression of >600 genes: central role of adrenergic/cAMP signaling. J Biol Chem 2009; 284: 7606-22.
21. MASRUHA M, SOUZA VIEIRA D, MINETT T et al.: Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain 2008; 9: 221-4.
22. HIRATA F, HAYAISHI O, TOKUYAMA T, SENO S: In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 1974; 249: 1311-3.
23. SLATS D, CLAASSEN JA, VERBEEK MM, OVEREEM S: Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin. Ageing Res Rev 2013; 12: 188-200.
24. PERMPOONPUTTANA K, GOVITRAPONG P: The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines. Neurotox Res 2013; 23: 189-99.
25. CAUMO W, LEVANDOVSKI R, HIDALGO MP: Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study. J Pain 2009; 10: 100-8.
26. TAHAN G, GRAMIGNOLI R, MARONGIU F et al.: Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acidinduced colitis in rats. Dig Dis Sci 2011; 56: 715-20.
27. LASTE G, de MACEDO IC, RIPOLL ROZISKY J, RIBEIRO da SILVA F, CAUMO W, TORRES IL: Melatonin administration reduces inflammatory pain in rats. J Pain Res 2012; 5: 359-62.
28. WILHELMSEN M, AMIRIAN I, REITER RJ, ROSENBERG J, GOGENUR I: Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011; 51: 270-7.
29. HUSSAIN SA, AL K, II, JASIM NA, GORIAL FI: Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011; 50: 267-71.
30. SRINIVASAN V, LAUTERBACH EC, HO KY, ACUNA-CASTROVIEJO D, ZAKARIA R, BRZEZINSKI A: Melatonin in antinociception: its therapeutic applications. Current neuropharmacology 2012; 10: 167-78.
31. WOLFE F, SMYTHE HA, YUNUS MB et al.: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
32. WOLFE F, CLAUW DJ, FITZCHARLES MA et al.: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatology 2011; 3: 1113-22.
33. MARQUES AP, SANTOS AMB, ASSUMPÇÃO A, MATSUTANI LA, LAGE LV, PEREIRA CAB: Validação da versão brasileira do Fibromyalgia Impact Questionnaire (FIQ). Rev Bras Reumatol 2006; 46: 24-31.
34. BERTOLAZI AN, MENNA B, SALDANHA S: Tradução, adaptação cultural e validação de dois instrumentos de avaliação do sono: escala de sonolência de Epworth e índice de qualidade de sono de Pittsburgh. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2008.
35. CICONELLI RM, FERRAZ MB, SANTOS W, MEINÃO I, QUARESMA MR: Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36) / Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure. Rev Bras Reumatol 1999; 39: 143-50.
36. GOUVEIA V, MILFONT T, FONSECA P, COELHO JM: Life Satisfaction in Brazil: Testing the Psychometric Properties of the Satisfaction With Life Scale (SWLS) in Five Brazilian Samples. Soc Indic Res 2009; 90: 267-77.
37. CORDERO MD, ALCOCER-GOMEZ E, CANOGARCIA FJ, de MIGUEL M, SANCHEZ-ALCAZAR JA, MORENO FERNANDEZ AM: [Low levels of serotonin in serum correlates with severity of fibromyalgia] (Article in Spanish)]. Med Clin (Barc) 2010; 135: 644-6.
38. SCHWARZ MJ, OFFENBAECHER M, NEUMEISTER A, ACKENHEIL M: Experimental evaluation of an altered tryptophan metabolism in fibromyalgia. Adv Exp Med Biol 2003; 527: 265-75.
39. WEBB SM: Fibromyalgia and melatonin: are they related? Clin Endocrinol 1998; 49: 161-2.
40. ALMAY BG, von KNORRING L, WETTERBERG L: Melatonin in serum and urine in patients with idiopathic pain syndromes. Psychiat Res1987; 22: 179-91.
41. CITERA G, ARIAS MA, MALDONADO-COCCO JA et al.: The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000; 19: 9-13.
42. LOEVINGER BL, SHIRTCLIFF EA, MULLER D, ALONSO C, COE CL: Delineating psychological and biomedical profiles in a heterogeneous fibromyalgia population using cluster analysis. Clin Rheumatol 2012; 31: 677-85.
43. DIJK DJ, DUFFY JF, SILVA EJ, SHANAHAN TL, BOIVIN DB, CZEISLER CA: Amplitude reduction and phase shifts of melatonin, cortisol and other circadian rhythms after a gradual advance of sleep and light exposure in humans. PloS One 2012; 7: e30037.
44. NATHAN PJ, BURROWS GD, NORMAN TR: The effect of dim light on suppression of nocturnal melatonin in healthy women and men. J Neural Transm 1997; 104: 643-8.
45. GOOLEY JJ, CHAMBERLAIN K, SMITH KA et al.: Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab 2011; 96: E463-72.
46. KOPP C, VOGEL E, RETTORI MC et al.: Antagonistic effects of S 22153, a new MT1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice. Pharmacol Biochem Be 1999; 64: 131-6.
47. UBEROS J, AUGUSTIN-MORALES MC, MOLINA CARBALLO A, FLORIDO J, NARBONA E, MUNOZ-HOYOS A: Normalization of the sleep-wake pattern and melatonin and 6-sulphatoxy-melatonin levels after a therapeutic trial with melatonin in children with severe epilepsy. J Pineal Res 2011; 50: 192-6.
48. WADE AG, FORD I, CRAWFORD G et al.: Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010; 8: 51.
49. REITER RJ, ACUNA-CASTROVIEJO D, TAN DX, BURKHARDT S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci 2001; 939: 200-15.
50. AMBRIZ-TUTUTI M, ROCHA-GONZALEZ HI, CRUZ SL, GRANADOS-SOTO V: Melatonin: a hormone that modulates pain. Life Sci 2009; 84: 489-98.
51. ZUROWSKI D, NOWAK L, CIESIELCZYK K, MACHOWSKA A, THOR PJ: [Effects of melatonin on nociception processes in experimentally model of neurophatic pain] (Article in Polish). Folia Med Cracov 2008; 49: 91-101.
52. REITER RJ, ACUNA-CASTROVIEJO D, TAN DX: Melatonin therapy in fibromyalgia. Curr Pain Headache Rep 2007; 11: 339-42.
53. ACUNA-CASTROVIEJO D, ESCAMES G, REITER RJ: Melatonin therapy in fibromyalgia. J Pineal Res 2006; 40: 98-9.
54. ULUS Y, AKYOL Y, TANDER B, DURMUS D, BILGICI A, KURU O: Sleep quality in fibromyalgia and rheumatoid arthritis: associations with pain, fatigue, depression, and disease activity. Clin Exp Rheumatol 2011; 29(Suppl. 69): S92-6.
55. MARTINEZ JE, BARAUNA FILHO IS, KUBOKAWA K, PEDREIRA IS, MACHADO LA, CEVASCO G: Evaluation of the quality of life in Brazilian women with fibromyalgia, through the medical outcome survey 36 item shortform study. Disabil Rehabil 2001; 23: 64-8.
56. BECKER RM, da SILVA VK, MACHADO FDA S et al.: Association between environmental quality, stress and APOE gene variation in fibromyalgia susceptibility determination. Rev Bras Reumatol 2010; 50: 617-24.